PRESS RELEASE
Current Neuroscience Journal
NEWS RELEASE: 4 Sep 2026
The study, "Decoding Oxidative Stress: Novel Mechanistic Pathways in Neurodegeneration," was published in Current Neuroscience Journal by Priyanka Yadav, Dinesh Kumar, Anil Kumar, and Sumit Kumar .
A new comprehensive review maps the molecular chain of events through which an imbalance in the brain's chemical environment drives the destruction of nerve cells, drawing together evidence across five major neurological diseases and making the case that treating oxidative stress effectively will require a much more precise understanding of how it behaves differently in each condition.
Why the Brain Is the Body's Most Vulnerable Organ When It Comes to Chemical Damage
Every cell in the body produces reactive oxygen species — unstable molecules generated as a byproduct of normal energy production — and every cell has defence systems designed to neutralise them before they cause damage. In most tissues, this balance is maintained reliably. The brain is perpetually under strain. The brain consumes a disproportionately large share of the body's oxygen relative to its size, is rich in the fatty molecules that reactive oxygen species attack most readily, and has comparatively weak antioxidant defences compared to other organs. Under normal conditions, low levels of these reactive molecules are not only harmless but actively useful — they participate in nerve cell signaling, help shape the connections between neurons that underlie learning and memory, and support immune responses in the brain. The problem begins when production outpaces the brain's ability to neutralise them. This state — known as oxidative stress — sets off a damaging cascade that attacks the fatty membranes surrounding cells, corrupts proteins, and damages DNA. Sustained over time, it disrupts the energy-generating machinery inside nerve cells, triggers chronic inflammation in brain tissue, and contributes to the formation of the abnormal protein clumps that are a hallmark of several neurodegenerative diseases. There is now substantial scientific evidence linking this process to Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease, and epilepsy — five conditions that collectively affect tens of millions of people worldwide and for which disease-modifying treatments remain elusive.
The Same Starting Point, Five Different Destinations: How Oxidative Stress Damages Each Disease Differently
One of the central contributions of this review is its careful separation of what these five diseases share from what makes each one mechanistically distinct — a distinction with important consequences for how treatments should be designed. At the shared level, all five conditions involve some combination of failing mitochondria (the energy-producing structures inside cells), weakened antioxidant defences, a toxic excess of stimulation at nerve synapses (known as excitotoxicity), chronic low-grade brain inflammation, and the buildup of misfolded proteins that the cell cannot clear. But the specific chemical pathways by which oxidative stress causes damage vary considerably across diseases. In Parkinson's disease, the chemical breakdown of dopamine — the neurotransmitter whose loss defines the condition — produces toxic byproducts called dopamine quinones that directly damage the nerve cells responsible for producing it, creating a self-reinforcing cycle of destruction. In ALS, mutations in the SOD1 gene — which normally produces a key antioxidant enzyme — generate a toxic, misfolded protein that disrupts the redox balance specifically in motor neurons, the cells that control voluntary movement. In Alzheimer's disease, the amyloid-beta protein fragments that accumulate in the brain act as catalysts for metal ions such as copper and iron, driving the production of highly reactive molecules that cause localised oxidative damage around amyloid plaques. In Huntington's disease, the mutant huntingtin protein physically impairs the function of mitochondria, reducing energy supply and increasing oxidative byproduct generation in the striatum, the brain region most affected by the disease. The review also addresses how oxidative damage is measured, examining a panel of biomarkers — including F2-isoprostanes and malondialdehyde as markers of fat damage, protein carbonyls and 3-nitrotyrosine as markers of protein damage, and 8-hydroxy-2′-deoxyguanosine as a marker of DNA damage — and drawing an important conceptual distinction between oxidative stress, which refers to the imbalance between production and defence, and oxidative damage, which refers to the measurable molecular harm. This distinction matters because a cell can be under oxidative stress without yet showing measurable damage if its defences are compensating, and treatments that address one without the other may miss the point.
Why Antioxidant Treatments Have Largely Failed — and What Needs to Change
Despite the strength of the evidence linking oxidative stress to neurodegeneration, antioxidant-based therapies have so far produced disappointing results in clinical trials. The review examines this translational gap directly and identifies several reasons why what works convincingly in laboratory models has not translated into clinical benefit in patients. Antioxidants given as drugs face the challenge of crossing the blood-brain barrier in sufficient concentrations to make a difference; they may act at the wrong point in the damage cascade or target the wrong reactive species; and the disease models used in preclinical research often do not capture the complexity and chronicity of human neurodegeneration. There is also a more fundamental concern: reactive oxygen species are not merely waste products that should be eliminated, as they play essential signalling roles in the healthy brain. Therefore, indiscriminate suppression of their production may disrupt normal cellular processes in addition to mitigating harmful oxidative effects. The authors argue that progress will require moving away from broad-spectrum antioxidant approaches toward treatments that target specific oxidative pathways relevant to each disease, at the appropriate stage of its progression and in the appropriate cellular compartment. Improving how oxidative damage biomarkers are used in clinical trials — both to select patients likely to benefit from antioxidant treatment and to measure whether a treatment is actually reducing brain oxidative stress — is also identified as a priority. The research was led by Dr. Sumit Kumar, who is the corresponding author, with co-authors Priyanka Yadav, Dinesh Kumar, and Anil Kumar.
Article title: Decoding Oxidative Stress: Novel Mechanistic Pathways in Neurodegeneration
Journal: Current Neuroscience Journal
Read more: https://bit.ly/4cezZrJ
10.2174/0129505623441229260714100114
Decoding Oxidative Stress: Novel Mechanistic Pathways in Neurodegeneration